Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | GRN | P28799 | 1/20 | 0.33 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | P2RY10 | O00398 | 1/20 | 0.31 |
| ▸ | GPR174 | Q9BXC1 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HRH2 | P25021 | 1/20 | 0.30 |
| ▸ | HRH1 | P35367 | 1/20 | 0.30 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.30 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL343636 | 1.00 | MAPK1 (0.41) | MAPK1CA1CA2KIF11SMN1; SMN2 | |
| SCHEMBL1588396 | 1.00 | MAPK1 (0.41) | MAPK1CA1CA2KIF11SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL29401055 | 0.98 | MAPK1 (0.40) | MAPK1CA1CA2KIF11SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL241035 | 0.98 | MAPK1 (0.40) | MAPK1CA1CA2KIF11SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL1304617 | 0.98 | MAPK1 (0.40) | MAPK1CA1CA2KIF11SMN1; SMN2 | |
| SCHEMBL3080102 | 0.83 | MAPK1 (0.41) | MAPK1CA1CA2GRNSORT1 | |
| SCHEMBL522783 | 0.83 | MAPK1 (0.41) | MAPK1CA1CA2GRNSORT1 | |
| SCHEMBL522812 | 0.83 | MAPK1 (0.41) | MAPK1CA1CA2GRNSORT1 | |
| Hydrochloric Acid SCHEMBL318950 | 0.82 | MAPK1 (0.40) | MAPK1CA1CA2HRH2HRH1 | |
| Hydrochloric Acid SCHEMBL522782 | 0.82 | MAPK1 (0.40) | MAPK1CA1CA2HRH2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109928971-B | Aryl substituted aminotetrahydropyrans and uses thereof | 广东东阳光药业股份有限公司 | 2024-01-16 | — | — | CN | disclosed |
| EP-2669266-B1 | Improved Method for Manufacturing Dipeptidyl Peptidase-IV Inhibitor and Intermediate | DONG A ST CO LTD (KR) | 2016-02-24 | — | — | EP | disclosed |
| EP-2669266-B1 | Improved Method for Manufacturing Dipeptidyl Peptidase-IV Inhibitor and Intermediate | DONG A ST CO LTD (KR) | 2016-02-24 | — | — | EP | disclosed |
| US-9249109-B2 | Method for preparing dipeptidyl peptidase-IV inhibitor and intermediate | DONG-A PHARMACEUTICAL CO., LTD. (KR) | 2016-02-02 | — | — | US | disclosed |
| US-9249109-B2 | Method for preparing dipeptidyl peptidase-IV inhibitor and intermediate | DONG-A PHARMACEUTICAL CO., LTD. (KR) | 2016-02-02 | — | — | US | disclosed |
| US-20160021882-A1 | APPLICATION OF BIOFILM FORMATION INHIBITING COMPOUNDS ENHANCES CONTROL OF CITRUS CANKER | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2016-01-28 | — | — | US | disclosed |
| US-20160021882-A1 | APPLICATION OF BIOFILM FORMATION INHIBITING COMPOUNDS ENHANCES CONTROL OF CITRUS CANKER | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2016-01-28 | — | — | US | disclosed |
| EP-2318361-B1 | SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS | NOVARTIS AG (CH) | 2015-09-23 | — | — | EP | disclosed |
| CN-102516184-B | DPP-IV inhibitor including beta-amino group, preparation method thereof and pharmaceutical composition containing the same for preventing and treating a diabetes or an obesity | DONG A ST CO LTD | 2015-03-25 | — | — | CN | disclosed |
| US-20150025241-A1 | METHOD FOR PREPARING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE | DONG-A PHARMACEUTICAL. CO., LTD (KR) | 2015-01-22 | — | — | US | disclosed |
| US-20110112076-A1 | SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS | NOVARTIS AG (CH) | 2011-05-12 | — | — | US | disclosed |
| EP-2318361-A1 | SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS | Novartis AG (CH) | 2011-05-11 | — | — | EP | disclosed |
| EP-1966198-B1 | 2-AMINO-3,4-DIHYDRO-PYRIDO[3,4-D]PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-16 | — | — | EP | disclosed |
| CN-101663282-A | DPP-IV inhibitor comprising beta-amino group, method for preparing the same and pharmaceutical composition for preventing and treating diabetes or obesity comprising the same | DONG A PHARM CO LTD | 2010-03-03 | — | — | CN | disclosed |
| WO-2010007027-A1 | SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS | NOVARTIS AG (CH) | 2010-01-21 | — | — | WO | disclosed |
| US-7531545-B2 | 2-amino-3,4-dihydro-pyrido[3,4-d]pyrimidine derivatives useful as inhibitors of β-secretase (BACE) | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-05-12 | — | — | US | disclosed |
| EP-1966198-A1 | 2-AMINO-3,4-DIHYDRO-PYRIDOÝ3,4-D¨PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-09-10 | — | — | EP | disclosed |
| US-7314940-B2 | For therapy and prophylaxis of neurodegenerative disorders related to apoptosis and/or inflammation | EISAI CO., LTD. (JP) | 2008-01-01 | — | — | US | disclosed |
| US-20070259898-A1 | NOVEL 2-AMINO-3,4-DIHYDRO-PYRIDO[3,4-D]PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF beta-SECRETASE (BACE) | BAXTER ELLEN E | 2007-11-08 | — | — | US | disclosed |
| WO-2007050612-A1 | 2-AMINO-3,4-DIHYDRO-PYRIDO[3,4-D]PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025241-A1 | METHOD FOR PREPARING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE | DPP4, DPP3, DPP7 | MAPK1 4349/4885CA1 838/4885CA2 1008/4885 |
| US-20110112076-A1 | SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS | MMP13, MMP11, MMP14 | MAPK1 585/4885CA1 123/4885CA2 177/4885 |
| US-20070259898-A1 | NOVEL 2-AMINO-3,4-DIHYDRO-PYRIDO[3,4-D]PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF beta-SECRETASE (BACE) | BACE2, PSEN2, BACE1 | MAPK1 4255/4885CA1 3872/4885CA2 2372/4885 |
| US-20160021882-A1 | APPLICATION OF BIOFILM FORMATION INHIBITING COMPOUNDS ENHANCES CONTROL OF CITRUS CANKER | XDH, MYB, DDC | MAPK1 1232/4885CA1 4039/4885CA2 3012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.